Scalp Psoriasis and Biologic Agents: A Review

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Scalp-localized psoriasis is a common and challenging manifestation of plaque psoriasis.
• Symptoms like scaling, erythema, and pruritus significantly impact patients' psychological well-being and quality of life.
• Existing treatments often struggle with efficacy and long-term disease control.

Purpose of the Study:

• To evaluate the efficacy of biologics and small molecules in managing scalp psoriasis symptoms.
• To assess the long-term maintenance capabilities of these therapies in plaque psoriasis.
• To determine the impact of these treatments on patients' quality of life.

Main Methods:

• Systematic review of clinical trials and observational studies.
• Analysis of Psoriasis Area and Severity Index (PASI) scores for symptom severity.
• Evaluation of Dermatology Life Quality Index (DLQI) for quality of life assessment.
• Assessment of treatment response and maintenance of efficacy over time.

Main Results:

• Biologics and small molecules demonstrate significant efficacy in reducing psoriasis symptoms (PASI scores).
• These advanced therapies lead to substantial improvements in patients' quality of life (DLQI scores).
• Evidence suggests potential for long-term disease control and maintenance of therapeutic benefits.

Conclusions:

• Biologics and small molecules represent effective therapeutic options for scalp-localized plaque psoriasis.
• These treatments offer a promising approach to managing symptoms and improving the quality of life for affected individuals.
• Further research is warranted to optimize long-term management strategies and assess comparative effectiveness.